Briefing
Circulating tumor DNA (ctDNA) to guide response-adapted bladder preservation in muscle invasive bladder cancer (MIBC).
Estimated 2-year metastasis-free survival was 79.8% in the RETAIN-2 ITT population; the abstract states RETAIN-2 is expected to meet its primary MFS endpoint. Among 22 active-surveillance patients, 16 (73%) remained metastasis-free with an intact bladder. Post-treatment ctDNA negativity or clearance predicted lower recurrence (34.8% and 43.8%) than persistent positivity or non-clearance (85.7% and 91.7%). Among active-surveillance patients who were ctDNA-negative after treatment, 24-month MFS was 82.4% but 24-month RFS was 50.7%, driven by local recurrences: 19 of 22 who recurred on active surveillance were ctDNA-negative after treatment.
- Design: LBA
- n: 71 evaluable RETAIN-2 patients; combined ctDNA analysis across RETAIN-1/2: 274 timepoints from 111 patients
- Assay: Signatera (named in the abstract)